• Pfizer Inc., of New York, said the FDA accepted for review the new drug application for tafamidis meglumine, its oral treatment for transthyretin familial amyloid polyneuropathy, a rare, progressive and fatal neurodegenerative disease that affects about 8,000 patients worldwide. Tafimidis, which Pfizer gained through its 2010 acquisition of privately held FoldRx Pharmaceuticals Inc., of Cambridge, Mass., was granted a priority review and has a PDUFA date in June 2012. Last year, the drug was approved in Europe, where it's sold under the brand name Vyndaqel.